Development of a Gastric Cancer Screening Intervention for H. Pylori Carriers Based on the Health Belief Model (HBM-GCS)
Development of a Gastric Cancer Screening Intervention Program for Helicobacter Pylori Carriers Based on the Health Belief Model
Gastric cancer (GC) remains a major global public health challenge. It often causes no obvious symptoms in the early stage, so most patients are diagnosed at an advanced stage. This highlights the importance of gastric cancer screening among high-risk populations to achieve early detection and improve survival outcomes. People infected with Helicobacter pylori (Hp) are at high risk of gastric cancer. Hp is one of the most common bacterial infections worldwide. It initiates carcinogenesis by triggering chronic atrophic gastritis and intestinal metaplasia, known as the Correa cascade. However, the acceptance of gastric cancer screening among Hp-infected individuals is still unsatisfactory. To our knowledge, there are few theory-based interventions designed to help Hp-infected people make decisions about gastric cancer screening and increase screening uptake. Therefore, based on our previous systematic review, this study aims to develop a health promotion program to improve gastric cancer screening participation among Hp-infected individuals in mainland China. Participants in the intervention group will receive a comprehensive health promotion program, including a 30-minute health education session. They will receive a 15-minute telephone follow-up with gastric cancer screening information in week 2, and additional 10-minute telephone follow-ups at weeks 2, 4, and 6 to help participants identify and overcome barriers to gastric cancer screening. Participants in the control group will receive routine care. Data on gastric cancer screening participation will be collected at the end of the intervention. Findings from this study will be valuable for gastric cancer prevention among people with Hp infection.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Participants in the intervention group will receive the following multi-session health promotion intervention. The details are as follows.
Screening benefit construction (30 min). In the first week, education will be delivered through face-to-face for the following information:
(1) Hp infection and increased gastric cancer risk; (2) gastric cancer screening recommendations regarding eligibility, available screening tests, and recommended screening intervals; (3) pros/advantages of undergoing gastric cancer screening; (4) cons/disadvantages or uncertainties of undergoing gastric cancer screening; (5) implications of positive screening results; and (6) health costs and service information. The educational material will be presented in a self-made manual, which will be explained and distributed to each participant.
Screening barrier navigation (15 min). It will be conducted in the second week by telephone. The nurse counsellor will help participants resolve individual barriers related to gastric cancer screening. The tailored content includes:
(1) Q&A about gastroscopy screening; (2) gastroscopy appointment procedure; (3) hospital and transportation information; (4) medical insurance consultation; (5) precautions for the examination.
Screening self-efficacy reinforcement (10 min each). At the fourth and sixth weeks, the nurse counsellor will work with participants through a telephone-based way (with WeChat as an auxiliary tool) to strengthen confidence in completing gastric cancer screening, in which participants will: (1) track the progress of screening arrangements; (2) receive home health guidance while waiting for the screening examination.
Participants in the control group will receive routine health care for Hp infection without this theory-based gastric cancer screening promotion program.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Mengyao Gao, MN
- Phone Number: (86)15870682367
- Email: 15870682367@163.com
Study Contact Backup
- Name: Caixia Li, PhD
- Phone Number: (86) 19867712062
- Email: licx23@mail.sysu.edu.cn
Study Locations
-
-
Guangdong
-
Shenzhen, Guangdong, China, 518000
- The University of Hong Kong-Shenzhen Hospital
-
Contact:
- Mengyao Gao, MN
- Phone Number: (86)15870682367
- Email: 15870682367@163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged between 45 and 74 years.
- Diagnosed with *Helicobacter pylori* infection confirmed by urea breath test (UBT), serological antibody test, or stool antigen test.
- Have adequate communication, reading, and comprehension ability.
- Provide informed consent, voluntarily participate in the study, and cooperate with all study procedures.
Exclusion Criteria:
-
1. Previously diagnosed with gastric cancer or other advanced malignant tumors. 2. Cognitive impairment, severe hepatic or renal insufficiency, psychiatric disorders, or severe physical illness that prevents cooperation with the interview.
3. Pregnant or breastfeeding women.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Experimental: Health Belief Model-based intervention group
Provide education, tailored information, barrier counseling, and decision support regarding gastric cancer screening for Helicobacter pylori-infected individuals. |
Provide health education, tailored information, barrier counseling and follow-up regarding gastric cancer screening for Helicobacter pylori-infected individuals. |
|
Other: Control group
Usual care provided by the hospital, including one-page written education material on gastroscopy. |
Usual care provided by the hospital, including one-page written education material on gastroscopy. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Gastric cancer screening intention
Time Frame: Immediately and 6 weeks after intervention
|
Participants' behavioral tendency and psychological readiness to actively seek and undergo gastroscopy within the next 5 years. |
Immediately and 6 weeks after intervention
|
|
Gastroscopy completion rate
Time Frame: 6 weeks after intervention
|
An objective outcome is defined as the number of participants who complete gastroscopy after intervention. The gastroscopy completion rates among Helicobacter pylori-infected participants in the two groups will be compared, serving as the key quantitative indicator to evaluate whether the intervention improves actual screening behavior. |
6 weeks after intervention
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Gastric cancer screening knowledge score
Time Frame: Immediately and 6 weeks after intervention
|
Assessed with knowledge items from Huang et al. (2022). The scale measures participants' knowledge of gastric cancer risk factors and warning symptoms, consisting of 24 items on risk factors and 14 items on warning symptoms. |
Immediately and 6 weeks after intervention
|
|
Total score of the Health Belief Model (HBM) questionnaire for gastric cancer screening
Time Frame: Immediately and 6 weeks after intervention
|
This subscale was developed based on the five-dimensional HBM framework proposed by Becker (1974), including perceived susceptibility to gastric cancer (3 items), perceived severity (3 items), perceived benefits of gastric cancer screening (2 items), perceived barriers to screening (5 items), and cues to action (3 items). The total score of the five dimensions is calculated. |
Immediately and 6 weeks after intervention
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Mengyao Gao, MN, Kiang Wu Nursing College of Macau(KWNC)
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Gastric Cancer Screening
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.